» Articles » PMID: 6200784

Biochemical Changes in Dementia Disorders of Alzheimer Type (AD/SDAT)

Overview
Journal Neurobiol Aging
Publisher Elsevier
Date 1983 Jan 1
PMID 6200784
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

In postmortem investigations of patients with dementia of Alzheimer type (AD/SDAT) (n = 14) the brain weight was significantly reduced when compared to controls (n = 16). In four AD/SDAT-brain parts investigated the concentrations of 5-hydroxy-tryptamine and noradrenaline were significantly reduced while 3-methoxy-4-hydroxyphenylglycol was significantly increased. In the caudate nucleus of the AD/SDAT-brains the concentrations of dopamine and homovanillic acid were significantly reduced. The activity of monoamine oxidase B was increased suggesting a proliferation of extra neuronal tissue in the AD/SDAT-brains. The activity of choline acetyl transferase was reduced in the four brain parts investigated, showing a general reduction in the acetylcholine system in the AD/SDAT-brains. The ganglioside concentration was significantly reduced suggesting a reduced density of nerve endings in the demented brains. The AD/SDAT-group was according to rating scales severely demented. Patients with an early onset of the dementia disease were more severely intellectually reduced and had more pronounced biochemical disturbances than those with a late onset of the dementia.

Citing Articles

A PAM of the α-Adrenergic receptor rescues biomarker, long-term potentiation, and cognitive deficits in Alzheimer's disease mouse models without effects on blood pressure.

Papay R, Stauffer S, Perez D Curr Res Pharmacol Drug Discov. 2023; 5:100160.

PMID: 37448695 PMC: 10336260. DOI: 10.1016/j.crphar.2023.100160.


Cerebrospinal fluid and positron-emission tomography biomarkers for noradrenergic dysfunction in neurodegenerative diseases: a systematic review and meta-analysis.

Lancini E, Haag L, Bartl F, Ruhling M, Ashton N, Zetterberg H Brain Commun. 2023; 5(3):fcad085.

PMID: 37151227 PMC: 10154713. DOI: 10.1093/braincomms/fcad085.


In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer's disease phases.

Sala A, Caminiti S, Presotto L, Pilotto A, Liguori C, Chiaravalloti A Alzheimers Res Ther. 2021; 13(1):187.

PMID: 34772450 PMC: 8588696. DOI: 10.1186/s13195-021-00925-1.


Tyr-Trp administration facilitates brain norepinephrine metabolism and ameliorates a short-term memory deficit in a mouse model of Alzheimer's disease.

Ichinose T, Murasawa H, Ishijima T, Okada S, Abe K, Matsumoto S PLoS One. 2020; 15(5):e0232233.

PMID: 32365077 PMC: 7197849. DOI: 10.1371/journal.pone.0232233.


MAOA-VNTR Genotype Effects on Ventral Striatum-Hippocampus Network in Alzheimer's Disease: Analysis Using Structural Covariance Network and Correlation with Neurobehavior Performance.

Chang H, Chang Y, Tsai S, Huang C, Hsu S, Liu M Mol Neurobiol. 2018; 56(6):4518-4529.

PMID: 30338484 DOI: 10.1007/s12035-018-1394-0.